Loading stock data…
$10.29-0.21 (-1.99%)
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
Cybin D/B/A Helus Pharma in the Healthcare sector is trading at $10.50 with a market capitalization of $994M. Wall Street consensus targets $40.15 (10 analysts), implying a +282.4% move over the next 12 months. The stock is currently 31% below its 52-week high of $15.15, remaining 39.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$49.08M↓ | -$47.86M↓ | -$41.21M↓ | -$28.89M↓ | -$24.62M |
| Net Income | -$47.82M↓ | -$46.99M↓ | -$42.67M↓ | -$33.72M↓ | -$24.61M |
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clin...